Protherics product update

Protherics (LSE:PTI) said its angiotensin vaccine to treat hypertension elicited antibodies against angiotensin in placebo-controlled Phase I single and multiple dose studies in 50 healthy volunteers. The company said there were indications that those antibodies blocked angiotensin's blood pressure raising effects. PTI expects to begin an 18-month Phase II dose optimization program with the vaccine in hypertension patients. ...